Direct Dose Equivalence Cannot be Established
There is no established dose equivalence between 30 mg of tirzepatide and retatrutide because 30 mg of tirzepatide does not exist as an approved dose, and no head-to-head comparative trials have established dose equivalency between these two medications.
Critical Context
The FDA-approved maximum dose of tirzepatide (Mounjaro) is 15 mg weekly, not 30 mg 1. The approved dosing escalation starts at 2.5 mg and increases in 2.5 mg increments to a maximum of 15 mg weekly 1. A 30 mg dose is not part of the approved dosing regimen and would be considered off-label and potentially unsafe.
Available Dosing Information
Tirzepatide (FDA-Approved)
- Maximum approved dose: 15 mg weekly 1
- Achieves approximately 20.9% weight loss at 72 weeks 2
- Dual GIP/GLP-1 receptor agonist 2
Retatrutide (Investigational)
- Phase 2 trial doses: 1 mg, 4 mg, 8 mg, and 12 mg weekly 3
- The 12 mg dose achieved 24.2% weight loss at 48 weeks 3
- Triple agonist (GIP/GLP-1/glucagon receptors) 3, 4
Comparative Efficacy Data
While no direct equivalence exists, network meta-analysis data suggests:
- Retatrutide 12 mg produced 22.10% body weight reduction 5
- Tirzepatide 15 mg produced 16.53% body weight reduction 5
- Retatrutide 8 mg produced 20.70% body weight reduction 5
Based on weight loss efficacy, tirzepatide 15 mg (the maximum approved dose) appears roughly comparable to retatrutide 8 mg, while retatrutide 12 mg demonstrates superior efficacy 5.
Important Caveats
- Retatrutide is not FDA-approved and remains investigational 3, 4
- These medications have different mechanisms of action (dual vs. triple agonist) 2, 4
- Safety profiles differ, particularly regarding gastrointestinal side effects and heart rate changes 3
- Direct dose conversion is not clinically appropriate or validated
If considering alternative dosing of tirzepatide beyond 15 mg weekly, this would be off-label, lacks safety data, and is not recommended based on current FDA labeling 1.